Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) issued its earnings results on Monday. The company reported ($2.21) earnings per share for the quarter, Zacks reports. The business had revenue of $0.67 million for the quarter.
Cyclacel Pharmaceuticals Price Performance
Cyclacel Pharmaceuticals stock opened at $0.97 on Tuesday. The firm has a 50 day moving average price of $1.04. The firm has a market capitalization of $4.76 million, a P/E ratio of -0.01 and a beta of -0.45. Cyclacel Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $100.75.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research note on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.
Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.
See Also
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
